Client Success
We leverage our unparalleled relationships across the life sciences ecosystem to connect the right leaders with the right companies.
Recent Client Success
Filter by placement
CBO|November 30, 2022
Chief Corporate Development Officer
Client Team Lead: Matt Toner
Client: Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of four senior leaders with significant industry experience in both small and large…
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of four senior leaders with significant industry experience in both small and large…
CMO|November 8, 2022
Executive Vice President, Chief Medical Officer
Client Team Lead: Sarah McKenna
Client: Akari Therapeutics, Plc
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of John F. Neylan, III, MD, as Executive Vice President, Chief Medical Officer, effective today.
…
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of John F. Neylan, III, MD, as Executive Vice President, Chief Medical Officer, effective today.
…
CEO|September 28, 2022
President, Chief Executive Officer
Client Team Lead: Matt Toner
Client: Reunion Neuroscience Inc.
Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, announced the appointment…
Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, announced the appointment…
VP|September 20, 2022
Vice President, Real World Evidence & Outcomes
Client Team Lead: John Spencer
Client: Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through its proprietary blood tests, vast data sets, and advanced analytics.
Guardant sought to change the global landscape from diagnosing cancer to screening…
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through its proprietary blood tests, vast data sets, and advanced analytics.
Guardant sought to change the global landscape from diagnosing cancer to screening…
CEO|September 7, 2022
Chief Executive Officer
Client Team Lead: John Spencer
Client: Sengenics LLC.
Sengenics LLC, driving the discovery of next-gen biomarkers, announces that Jerry Williamson has been appointed the company’s Chief Executive Officer, effective immediately. With more than 30 years of experience in bioscience markets for life science research, diagnostics…
Sengenics LLC, driving the discovery of next-gen biomarkers, announces that Jerry Williamson has been appointed the company’s Chief Executive Officer, effective immediately. With more than 30 years of experience in bioscience markets for life science research, diagnostics…
Director|July 11, 2022
Medical Director – CNS
Client Team Lead: Andy Cronin
Client: Alkahest
Alkahest, a subsidiary of Grifols, is a biotechnology company focused on developing therapies derived from blood to treat various neurological diseases.
For their Medical Director – CNS, Alkahest needed a neurologist to drive the clinical strategy for their…
Alkahest, a subsidiary of Grifols, is a biotechnology company focused on developing therapies derived from blood to treat various neurological diseases.
For their Medical Director – CNS, Alkahest needed a neurologist to drive the clinical strategy for their…
CFO|June 27, 2022
Chief Financial Officer
Client Team Lead: Matt Toner
Client: Aptose Biosciences, Inc.
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the…
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the…
BOD|June 24, 2022
Board of Directors
Client Team Lead: Caroline Hunt
Client: Pixium Vision SA
Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the appointment…
Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the appointment…
Learn More About Our Search Opportunities
Need help finding the right opportunity? We'll be happy to help!